StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alexion Pharmaceuticals (ALXN) Reiterated Buy at Nomura but EPS Expected to be Below Consensus
October 16, 2019 6:35 AM
Nomura/Instinet analyst Christopher Marai reiterated a Buy rating and $165.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) ahead of 3Q19 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments